Viking Therapeutics Inc VKTX:NASDAQ
RT Quote | Last NASDAQ LS, VOL From CTA | USD
After Hours: Last | 7:14 PM EDT29.20
-0.13 (-0.44%)
-0.13 (-0.44%)Volume
26,996
Close
29.33
+0.04 (+0.14%)
+0.04 (+0.14%)Volume
1,413,951
52 week range
22.96 - 43.15
- Open29.39
- Day High29.80
- Day Low29.06
- Prev Close29.29
- 52 Week High43.15
- 52 Week High Date11/12/25
- 52 Week Low22.96
- 52 Week Low Date09/17/25
Latest On Viking Therapeutics Inc
Key Stats
- Market Cap3.405B
- Shares Out116.11M
- 10 Day Average Volume1.83M
- Dividend-
- Dividend Yield-
- Beta0.69
Latest On Viking Therapeutics Inc
KEY STATS
- Open29.39
- Day High29.80
- Day Low29.06
- Prev Close29.29
- 52 Week High43.15
- 52 Week High Date11/12/25
- 52 Week Low22.96
- 52 Week Low Date09/17/25
- Market Cap3.405B
- Shares Out116.11M
- 10 Day Average Volume1.83M
- Dividend-
- Dividend Yield-
- Beta0.69
RATIOS/PROFITABILITY
- EPS (TTM)-4.15
- P/E (TTM)-7.06
- Fwd P/E (NTM)-6.91
- EBITDA (TTM)-501.998M
- ROE (TTM)-70.04%
- Revenue (TTM)-
- Gross Margin (TTM)-
- Net Margin (TTM)-
- Debt To Equity (MRQ)-
EVENTS
- Earnings Date07/21/2026(est)
- Ex Div Date-
- Div Amount-
- Split Date-
- Split Factor-
Content From Our Affiliates
Related Video
watch now
Profile
MOREViking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for the treatment of metabolic and endocrine disorders. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. It is evaluating an oral formulation of VK2735 in a Phase II trial. It is also developing...
Lawson Macartney Ph.D.
Independent Chairman of the Board
Brian Lian Ph.D.
President and Chief Executive Officer, Director
Marianne Mancini
Chief Operating Officer
Greg Zante CPA
Chief Financial Officer
Address
9920 Pacific Heights Blvd, Suite 350
San Diego, CA
92121
United States